Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. 

The abstract, “Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial” will be presented as part of Late Breaking Research: Clinical Trials on Saturday, March 2 between 1:00 p.m. and 4:00 p.m. in Ballroom A.
In addition, a second abstract, “Improvement of Itch and Pain in Patients with Prurigo Nodularis Treated with Serlopitant: Secondary analysis of Phase 2 Clinical Trial” was accepted as an oral presentation and online e-poster.  Presentations will be held on Friday, March 1 and Saturday, March 2.